Combination treatment with 17-AAG and a SIRT1 inhibitor successfully targeted CSCs that are resistant to current therapies in CD44high chronic myeloid leukemia [35]. Here, SIRT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.